Articles From: Spectranetics Announces Common Stock Offering to SPEEDO USA Partners with Leading Dance-Fitness Brand Zumba on Exclusive New Swimwear Collection

COLORADO SPRINGS, Colo., April 23, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) , today announced that it has commenced an underwritten public offering of approximately 4,750,000 shares of common stock.

COLORADO SPRINGS, Colo., May 6, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced the Food and Drug Administration's (FDA) approval of its adjunct analysis plan associated with the EXCITE ISR clinical trial, studying the treatment of in-stent restenosis (ISR) in the legs.

COLORADO SPRINGS, Colo., April 25, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) , today announced the pricing of a previously announced underwritten registered public offering of 4,750,000 shares of its common stock at a public offering price of $18.00 per share.

COLORADO SPRINGS, Colo., April 11, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release 2013 first quarter financial results after market close on Tuesday, April 23, 2013.

COLORADO SPRINGS, Colo., Feb.

Spectrum Brands Holdings, Inc. (NYSE: SPB) announced today that it has completed the acquisition of the residential lockset business of Tong Lung Metal Industry Co.

Spectrum Brands Holdings, Inc. (NYSE: SPB) , a global and diversified consumer products company with market-leading brands, announced that its Board of Directors today declared a quarterly dividend of $0.25 per share on the Company’s common stock.

Spectrum Brands Holdings, Inc. (NYSE: SPB) announced that its Board of Directors today declared a quarterly dividend of $0.25 per share on the Company’s common stock.

Spectrum Brands Holdings, Inc. (NYSE: SPB) , a global and diversified consumer products company with market-leading brands, today reported record fiscal 2013 second quarter results for the period ended March 31, 2013 and reiterated its outlook for a fourth consecutive year of record performance for the legacy business, which excludes the Hardware & Home Improvement (HHI) business, from expectations for stronger second half results.

Spectrum Brands Holdings, Inc. (NYSE: SPB) , a global consumer products company with market-leading brands, announced today that it will participate in the Barclays 2013 High Yield Bond and Syndicated Loan Conference on Wednesday, May 22 in Chicago.

Spectrum Brands Holdings, Inc. (NYSE: SPB) , a diversified and global consumer products company with market-leading brands, announced today it will release its fiscal 2013 second quarter financial results for the period ended March 31, 2013 after the markets close on Tuesday, April 30.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has reacquired development and commercialization rights for apaziquone in the United States, Europe and other territories pursuant to an agreed-upon restructuring of Spectrum’s collaboration with Allergan, Inc. In exchange, Allergan will receive a royalty on future revenue.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the first quarter 2013 financial results, provide an update on the Company's business, and discuss expectations for the future.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the fourth quarter and fiscal year 2012 financial results, provide an update on the Company's business, and discuss expectations for the future.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Lee F.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has gained global development and commercialization rights to Ligand Pharmaceuticals’ (NASDAQ: LGND) Captisol-enabled ® , propylene glycol-free (PG-free) melphalan.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as “LAPS-GCSF”), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company’s proprietary LAPSCOVERY™ Technology.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today commented on anticipated first quarter performance and updated its 2013 outlook for the Company.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended March 31, 2013.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today reported financial results for the three- and twelve-month periods ended December 31, 2012.

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor, LLP announce that a federal class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (“Spectrum Pharmaceuticals” or “Company”) (NasdaqGS: SPPI). The firms are investigating additional legal claims against the officers and Board of Directors of Spectrum Pharmaceuticals during the period of August 8, 2012 to March 12, 2013 (the “Class Period”). If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at WBriscoe@TheBriscoeLawFirm.com , or Zachary Groover at Powers Taylor, LLP, toll free (877) 728-9607, via email at zach@powerstaylor.com .

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the 25th Annual ROTH Conference being held at The Ritz-Carlton Hotel in Laguna Niguel, California.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2013 Health Care Conference being held at Encore at the Wynn in Las Vegas, NV.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Leerink Swann 2013 Global Healthcare Conference being held at The Waldorf=Astoria Hotel in New York City.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the RBC Capital Markets Healthcare Conference being held at the New York Palace Hotel in New York City.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the UBS Global Healthcare Conference being held at Sheraton New York Hotel in New York City.

SAN DIEGO and HENDERSON, Nev.

http://media.marketwire.com/attachments/201206/57671_speedemissionslogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1003691&ProfileId=051205&sourceType=1 ATLANTA, GA --

ATLANTA , May 7, 2013 /PRNewswire/ --  Speedemissions, Inc. (OTC Bulletin Board: SPMI) , a leading vehicle emissions testing and safety inspections company with stores in Atlanta , Houston , St.

SPEEDO USA , a division of PVH Corp.